Page last updated: 2024-12-05

sibutramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sibutramine is a medication that was used to treat obesity. It acts as a serotonin-norepinephrine reuptake inhibitor (SNRI) and is believed to work by increasing feelings of fullness and decreasing appetite. It was synthesized by the pharmaceutical company Knoll AG in the 1980s. Sibutramine was once a widely prescribed weight-loss medication, but it was withdrawn from the market in many countries in 2010 due to concerns about an increased risk of cardiovascular events, including heart attacks and strokes. Despite its withdrawal, sibutramine remains an important compound for research as its mechanism of action provides insights into appetite regulation and potential therapeutic targets for obesity treatment. Researchers continue to study sibutramine's effects on the brain, its metabolism, and its potential interactions with other medications, seeking to understand the risks and benefits of this drug. '

sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5210
CHEMBL ID1419
CHEBI ID9137
SCHEMBL ID2955
MeSH IDM0162538

Synonyms (78)

Synonym
AC-15773
HMS3394P05
AB00949538-11
gtpl2586
hsdb 7209
meridia
1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine
SPECTRUM_001961
BSPBIO_002737
SPECTRUM5_001440
sibutramine
C07247
106650-56-0
DB01105
sibutramine [inn:ban]
cyclobutanemethanamine, 1-(4-chlorophenyl)-n,n-dimethyl-alpha-(2-methylpropyl)-
dea no. 1675
sibutramina [spanish]
medaria
sibutraminum [latin]
KBIOSS_002516
KBIO2_005076
KBIO2_007644
KBIO2_002508
KBIO3_001957
KBIOGR_001653
SPBIO_001612
SPECTRUM4_001137
SPECTRUM3_001009
SPECTRUM2_001686
NCGC00092357-02
MLS001066619
MLS001401362
smr000238156
HMS2052P05
HMS2090N17
cf-alli
racemic sibutramine
CHEMBL1419
butramin
chebi:9137 ,
D08513
sibutramine (inn)
butramin (tn)
STK802066
AKOS004119970
(r)-ddms
bts 54 524
wv5ec51866 ,
unii-wv5ec51866
sibutraminum
sibutramina
BBL010956
bdbm84742
nsc_5210
cas_106650-56-0
HMS2272C06
CCG-101166
NCGC00092357-04
cyclobutanemethanamine, 1-(4-chlorophenyl)-n,n-dimethyl-.alpha.-(2-methylpropyl)-
sibutramine [mi]
(+/-)-1-(p-chlorophenyl)-.alpha.-isobutyl-n,n-dimethylcyclobutanemethylamine
sibutramine [inn]
sibutramine [who-dd]
1-(4-chlorophenyl)-n,n-dimethyl-.alpha.-(2-methylpropyl)cyclobutanemethanamine
sibutramine [vandf]
(+/-)-sibutramine
AKOS022060500
NC00416
SCHEMBL2955
(.+/-.)-1-(p-chlorophenyl)-.alpha.-isobutyl-n,n-dimethylcyclobutanemethylamine
AB00949538_12
DTXSID1023578
{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}dimethylamine
SBI-0206737.P001
FT-0674580
BCP08127
Q424151

Research Excerpts

Overview

Sibutramine is an antiobesity drug that inhibits the reuptake of serotonin and noradrenalin in the hypothalamus. It was initially developed as a potential antidepressant and later approved for the management of obesity.

ExcerptReferenceRelevance
"Sibutramine is a non-selective serotonin-norepinephrine reuptake inhibitor orally administered for weight loss. "( Impact of timing of the anorexigen sibutramine administration on reproductive end-points of male rats.
Anselmo-Franci, JA; Borges, CS; Kempinas, WG; Lozano, AFQ; Missassi, G; Silva, PV; Silva, RF, 2020
)
2.28
"Sibutramine is a serotonin-norepinephrine-dopamine reuptake inhibitor, initially developed as a potential antidepressant and later approved for the management of obesity. "( Suicide Attempt in a Patient with Sibutramine Associated Psychosis.
Câmara Pestana, P; Ferreira, C; Ganança, L; Jerónimo, J; Santos, AL, 2022
)
2.44
"Sibutramine is an antiobesity drug that inhibits the reuptake of serotonin and noradrenalin in the hypothalamus. "( Transient thyrotoxicosis from thyroiditis induced by sibutramine overdose: a case report.
Chung, SI; Hahm, JR; Jung, JH; Jung, TS; Kim, HS; Kim, S; Kim, SK; Lee, SM; Yoo, SS, 2013
)
2.08
"Sibutramine is a weight loss agent recently withdrawn from the European market due to cardiovascular risk concerns. "( Sibutramine-associated psychotic symptoms and zolpidem-induced complex behaviours: implications for patient safety.
Cubała, WJ; Jakuszkowiak-Wojten, K; Krysta, K; Landowski, J; Nowak, P; Wiglusz, MS, 2013
)
3.28
"Sibutramine is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of obesity. "( Evaluation of the effect of acute sibutramine in female rats in the elevated T-maze and elevated plus-maze tests.
André, E; de Assunção, GL; de Barros, KS; de Medeiros, DM; de Paula Soares-Rachetti, V; de Sousa Pinto, IA; Gavioli, EC; Santos, RO; Soares, BL, 2014
)
2.12
"Sibutramine is a serotonin-norepinephrine reuptake inhibitor that was used for weight-loss management in obese patients. "( Effects of oral anorexiant sibutramine on the expression of cytochromes P450s in human hepatocytes and cancer cell lines.
Bachleda, P; Dvořák, Z; Knoppová, B; Vrzal, R, 2013
)
2.13
"Sibutramine is an anti-obesity drug that has been used worldwide but is indiscriminately consumed in Brazil."( Can Spirulina maxima reduce the mutagenic potential of sibutramine?
Araldi, RP; Carvalho, LB; de-Sá-Júnior, PL; Ito, ET; Mendes, TB; Santos, NP; Souza, EB, 2015
)
1.39
"Sibutramine is an anti-obesity medication whose effects on weight loss have been widely explored. "( Effect of Sibutramine on Plasma C-Reactive Protein, Leptin and Adipon ectin Concentrations: A Systematic Review and Meta-Analysis of Randomized Contr olled Trials.
De Vincentis, A; Derosa, G; Maffioli, P; Pedone, C; Picardi, A; Sahebkar, A; Vespasiani-Gentilucci, U, 2017
)
2.3
"Sibutramine is a weight loss agent, for use as an adjuvant to a comprehensive program of calorie restriction, exercise and behavioral therapy."( Sibutramine: current status as an anti-obesity drug and its future perspectives.
Henderson, DC; Sharma, B, 2008
)
2.51
"Sibutramine is an anti-obesity drug, which acts by inhibiting neuronal re-uptake of noradrenaline and serotonin. "( Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use.
Bayrak, F; Degertekin, M; Eroglu, E; Gemici, G; Kalkan, AK, 2009
)
2.03
"Sibutramine is a centrally acting serotonin/noradrenaline reuptake inhibitor that mainly increases satiety."( [Pharmacological therapy of obesity].
Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V, 2008
)
1.07
"Sibutramine is an amphetamine-like drug used for its weight reducing effect. "( Sibutramine-induced acute myocardial infarction in a young lady.
Chan, CK; Lau, FL; Ng, HW; Yim, KM; Yip, G, 2008
)
3.23
"Sibutramine is a serotonin-noradrenaline reuptake inhibitor, which acts centrally by promoting the feeling of satiety and decreasing caloric intake, thus resulting in weight loss."( Effect of antiobesity medications in patients with type 2 diabetes mellitus.
Choussein, S; Daskalopoulou, SS; Frangos, CC; Makri, AA; Petridou, ET, 2009
)
1.07
"Sibutramine is an inhibitor of norepinephrine and 5-HT reuptake largely used in the management of obesity. "( Multiple effects of sibutramine on ejaculation and on vas deferens and seminal vesicle contractility.
de Camargo, AC; Kiguti, LR; Lameu, C; Nojimoto, FD; Pereira, OC; Piffer, RC; Pupo, AS, 2009
)
2.12
"Sibutramine is a centrally acting neurotransmitter reuptake inhibitor used for the treatment of obesity. "( A retrospective review of California poison control system data of sibutramine exposures.
Cantrell, FL; Clark, RF; Ebrahimi, S; Ly, B; Minns, AB; Te, L, 2009
)
2.03
"Sibutramine is a centrally acting monoamine reuptake inhibitor prescribed as an appetite suppressant in the management of obesity. "( Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.
Babalola, KO; Bradley, S; Brown, G; Clarke, CP; Matthews, JC; McMahon, AW; Philipp, AW; Talbot, PS, 2010
)
2.06
"Sibutramine is a pharmacologic intervention for the treatment of obesity. "( Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects.
Chung, JY; Jang, SB; Lee, YJ; Park, K; Park, MS, 2011
)
2.06
"Sibutramine is a selective inhibitor of the reuptake of monoamines. "( An obesity drug sibutramine reduces brain natriuretic peptide (BNP) levels in severely obese patients.
Algul, B; Arif Yalcin, A; Ata, N; Dal, K; Kucukazman, M; Okhan Akin, K; Sinan Deveci, O; Taner Ertugrul, D; Tutal, E; Yavuz, B, 2010
)
2.15
"Sibutramine is a combined norepinephrine and serotonin reuptake inhibitor used as an antiobesity agent to reduce appetite and promote weight loss in combination with diet and exercise. "( Cardiovascular risk-benefit profile of sibutramine.
Scheen, AJ, 2010
)
2.07
"Sibutramine is an FDA-approved drug for body weight control; therefore, we chose this drug as the standard treatment medication in this study."( Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study.
Joo, NS; Kim, BT; Kim, CW; Kim, KM; Kim, SM; Lee, DJ, 2011
)
1.09
"Sibutramine is an anti-obesity agent that induces weight loss by selective inhibition of neuronal reuptake of serotonin and norepinephrine; however, it is associated with the risk of cardiovascular diseases (CVD), including heart attack and stroke. "( Proteome changes in rat plasma in response to sibutramine.
Choi, DK; Choi, JW; Joo, JI; Kim, DH; Oh, TS; Wang, X; Yun, JW, 2011
)
2.07
"Sibutramine is a serotonergic and adrenergic drug that reduces food intake and increases thermogenesis."( Drug treatment for obesity in the post-sibutramine era.
Cheung, BM, 2011
)
1.36
"Sibutramine is a drug globally used for the treatment of obesity. "( Acceleration of sperm transit time and reduction of sperm reserves in the epididymis of rats exposed to sibutramine.
Bellentani, FF; Fernandes, GS; Kempinas, WD; Kiguti, LR; Pacini, ES; Perobelli, JE; Pupo, AS,
)
1.79
"Sibutramine is a combined serotonin(5-HT) and noradrenaline (NA)re-uptake inhibitor. "( An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.
Carruba, MO; Nisoli, E, 2000
)
2.01
"Sibutramine is a centrally-acting agent which enhances satiety and thermogenesis by inhibiting serotonin and noradrenaline re-uptake."( Pharmacological management of obesity.
Hanif, MW; Kumar, S, 2002
)
1.04
"Sibutramine is a serotonin-noradrenaline (norepinephrine) reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet."( A benefit-risk assessment of sibutramine in the management of obesity.
Carruba, MO; Nisoli, E, 2003
)
1.33
"Sibutramine is a serotonin and norepinephrine reuptake inhibitor, used in the treatment of obesity. "( Acute cardiovascular effects of sibutramine in conscious rats.
Aspley, S; Bennett, T; Dunn, WR; Gardiner, SM; Heal, DJ; Woolard, J, 2004
)
2.05
"Sibutramine is an anti-obesity agent."( Effects of the sibutramine therapy on pulmonary artery pressure in obese patients.
Cetinkaya, A; Guven, A; Koksal, N; Ozdemir, R; Sokmen, G, 2004
)
1.4
"Sibutramine is an effective appetite suppresser agent, but treatment is often complicated with side effects, including palpitations and hypertension. "( Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study.
Baykan, M; Durmus, I; Erem, C; Ersoz, HO; Hacihasanoglu, A; Telatar, M; Ukinc, K, 2004
)
2.02
"Sibutramine is a US Food and Drug Administration- and European Committee for Proprietary Medicinal Products-approved medication with demonstrated efficacy in long-term obesity management."( Clinical use of sibutramine.
Ryan, DH, 2004
)
1.39
"Sibutramine is a cost-effective treatment for obesity when combined with diet and lifestyle advice."( Cost-effectiveness of sibutramine in the treatment of obesity.
Akehurst, R; Brennan, A; Warren, E,
)
1.89
"Sibutramine is a selective serotonin and noradrenaline re-uptake inhibitor approved for the long-term management of obesity. "( Sibutramine and the management of obesity.
Foreyt, JP; Poston, WS, 2004
)
3.21
"Sibutramine is a selective serotonin and noradrenaline reuptake inhibitor that is known to reduce body weight. "( Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
Hauner, H; Kurscheid, T; Lauterbach, K; Meier, M; Wendland, G, 2004
)
2.09
"Sibutramine is a drug used for the medical treatment of obesity. "( Sibutramine use in pregnancy: report of two cases.
Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F, 2004
)
3.21
"Sibutramine is an inhibitor of norepinephrine, dopamine and serotonina reuptake which inhibits food intake and increases thermogenesis."( [Pharmacological treatment of obesity].
Gomis Barbará, R,
)
0.85
"Sibutramine is an anorexiant drug that inhibits the reuptake of noradrenaline and serotonin, a pharmacological property shared with drugs clinically effective in treating anxiety pathologies. "( Effects of sibutramine on anxiety-related behaviours in rats.
de Oliveira, AM; de Paula Soares, V; Jorge, SD; Pobbe, RL; Zangrossi, H, 2004
)
2.16
"Sibutramine is a serotonin- and norepinephrine-reuptake inhibitor that reduces food intake by inducing early satiety and attenuates the decrease in basal energy expenditure associated with weight loss."( Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Berber, A; Campos-Franco, E; Fanghänel, G; Martínez-Rivas, L; Sánchez-Reyes, L; Yamamoto, J, 2004
)
1.5
"Sibutramine is an anti-obesity drug sold as a racemic mixture under the trademark Meridia or Reductil. "( The stereoselective biotransformation of the anti-obesity drug sibutramine in rat liver microsomes and in primary cultures of rat hepatocytes.
Link, M; Novotná, R; Skálová, L; Suchanová, B; Szotáková, B; Wsól, V, 2005
)
2.01
"Sibutramine is a drug with established efficacy in weight reduction and maintenance of weight loss."( A review of the metabolic effects of sibutramine.
Elisaf, MS; Filippatos, TD; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP, 2005
)
1.32
"Sibutramine is an orally administered, centrally acting antiobesity drug. "( Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study.
Kim, KA; Lee, GS; Park, JY; Park, PW; Suh, KH, 2004
)
2.01
"Sibutramine mesylate is a new anti-obesity drug. "( Safety pharmacology of sibutramine mesylate, an anti-obesity drug.
Kim, EJ; Park, EK; Suh, KH, 2005
)
2.08
"Sibutramine is a neuropharmacological drug that exerts central (CNS) and peripheral effects including noradrenaline (NA), and serotonin (5-HT) uptake inhibition. "( Neurochemical, neuroautonomic and neuropharmacological acute effects of sibutramine in healthy subjects.
Baez, S; Hernandez, G; Lechin, F; Orozco, B; Rodriguez, S; van der Dijs, B, 2006
)
2.01
"Sibutramine is a drug that is used in the treatment of obesity. "( Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up.
Carducci, B; Caruso, A; Cavaliere, AF; De Santis, M; Straface, G, 2006
)
2.09
"Sibutramine, however, is an exception."( Central nervous system biogenic amine targets for control of appetite and energy expenditure.
Gehlert, DR; Nelson, DL, 2006
)
1.06
"Sibutramine is a satiety-inducing serotonin-noradrenaline reuptake inhibitor that acts predominantly via its primary and secondary metabolites. "( The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes.
Bailey, CJ; Jones, RB; Richardson, DK, 2006
)
2.06
"For sibutramine, there is a rise in blood pressure and heart rate that may require discontinuation of the drug in a small percent of patients."( Drug treatment of the overweight patient.
Bray, GA; Ryan, DH, 2007
)
0.82
"Sibutramine is a noradrenaline and serotonin reuptake inhibitor which reduces body weight by about 4-5 kg but increases heart rate and arterial blood pressure."( [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
Zieba, R, 2007
)
1.06
"Sibutramine is a serotonin and norepinephrine reuptake intake inhibitor approved for the management of obesity. "( Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation.
Lee, J; Lee, TS; Teoh, T, 2008
)
2.06
"Sibutramine is a racemic mixture (RS) containing two equal forms of the R(+) and S(-) enantiomers."( Anorexic effect of (R)-sibutramine: comparison with (RS)-sibutramine [corrected] and (S)-sibutramine.
Bodhankar, SL; Gaur, V; Singhal, S; Thakurdesai, PA,
)
1.16
"Sibutramine is a novel new pharmacologic agent which is a specific reuptake inhibitor for norepinephrine and serotonin. "( Sibutramine: a novel new agent for obesity treatment.
Bray, GA; Kaiser, P; Ryan, DH, 1995
)
3.18
"Sibutramine is a beta-phenethylamine which blocks reuptake of norepinephrine and serotonin. "( A double-blind randomized placebo-controlled trial of sibutramine.
Bray, GA; Cerise, F; Gordon, D; Heidingsfelder, S; Ryan, DH; Wilson, K, 1996
)
1.99
"Sibutramine is a noradrenaline and 5-hydroxytryptamine reuptake inhibitor which causes weight loss in laboratory rodents via effects on both food intake and metabolic rate. "( Sibutramine: a review of the pharmacology of a novel anti-obesity agent.
Stock, MJ, 1997
)
3.18
"1. Sibutramine is a novel 5-hydroxytryptamine (5-HT) and noradrenaline reuptake inhibitor (serotonin-noradrenaline reuptake inhibitor, SNRI) which is currently being developed as a treatment for obesity. "( Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat.
Bearham, MC; Heal, DJ; Hutchins, LJ; Jackson, HC; Mazurkiewicz, SE; Needham, AM, 1997
)
1.13
"Sibutramine is a serotonin and norepinephrine reuptake inhibitor that has shown efficacy as a weight loss and weight maintenance agent. "( Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines.
Beake, B; Cole, JO; Kaiser, PE; Levin, A; Scheinbaum, ML, 1998
)
3.19
"Sibutramine is a reuptake inhibitor of 5-hydroxytryptamine and noradrenaline, being developed as a treatment for obesity."( Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice.
Bailey, CJ; Day, C, 1998
)
2.03
"Sibutramine is a serotonin and noradrenaline re-uptake inhibitor (SNRI) which induces weight loss via a dual mode of action: enhancing both satiety and energy expenditure. "( Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
De Leeuw, IH; Van Gaal, LF; Wauters, MA, 1998
)
2.03
"Sibutramine is an effective compound for the treatment of obesity, acting both on serotonergic and noradrenergic pathways. "( Thermogenic effects of sibutramine in humans.
Astrup, A; Hansen, DL; Macdonald, IA; Stock, MJ; Toubro, S, 1998
)
2.05
"Sibutramine is an orally administered centrally acting weight management agent apparently devoid of amphetamine-like abuse potential. "( Sibutramine. A review of its contribution to the management of obesity.
Goa, KL; McNeely, W, 1998
)
3.19
"Sibutramine is a weight control drug that inhibits the reuptake of both serotonin and norepinephrine. "( Sibutramine produces dose-related weight loss.
Blackburn, GL; Bray, GA; Ferguson, JM; Greenway, FL; Jain, AK; Mendel, CM; Mendels, J; Ryan, DH; Scheinbaum, ML; Schwartz, SL; Seaton, TB, 1999
)
3.19
"Sibutramine is a serotonin-norepinephrine reuptake-inhibitor effective in the treatment of obesity. "( Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.
Luque, CA; Rey, JA, 1999
)
3.19
"Sibutramine (Meridia) is a serotonin and norepinephrine reuptake inhibitor marketed for weight control. "( Abuse liability assessment of sibutramine, a novel weight control agent.
Hopper, JA; Mendel, CM; Schuh, LM; Schuster, CR, 2000
)
2.04
"Sibutramine is a serotonin and noradrenaline reuptake inhibitor exerting a weight reducing effect partly via its anorectic properties. "( Modalities of the food intake-reducing effect of sibutramine in humans.
Chapelot, D; Hanotin, C; Marmonier, C; Thomas, F, 2000
)
2
"Sibutramine is a tertiary amine that has been shown to induce dose-dependent weight loss and to enhance the effects of a low-calorie diet for up to a year. "( Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.
Astrup, A; Finer, N; Hilsted, J; James, WP; Kopelman, P; Rössner, S; Saris, WH; Van Gaal, LF,
)
1.98
"Sibutramine is a tertiary amine that has been shown to induce dose-dependent weight loss and enhance the effects of a low-calorie diet for up to a year. "( [The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial].
Astrup, AV; Hansen, DL; Hilsted, JC; Porsborg, PA; Toubro, S, 2001
)
2.11
"Sibutramine is a centrally acting inhibitor of noradrenaline and serotonine reuptake, thereby decreasing caloric intake and increasing energy expenditure."( Current pharmacological approaches to the treatment of obesity.
Hauner, H, 2001
)
1.03
"Sibutramine is an effective adjunct to oral hypoglycemic therapy in obese women with type 2 diabetes."( Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
Ertorer, EM; Gokcel, A; Guvener, N; Karakose, H; Tanaci, N; Tutuncu, NB, 2001
)
1.42
"Sibutramine is a new anorectic drug used for the treatment of obesity."( [Study of heart valve function on obese patients treated with sibutramine].
Astorga, R; García-Luna, PP; López-Pardo, F; Parejo, J; Pereira, JL; Rodríguez-Puras, MJ, 2002
)
1.28
"Sibutramine is a serotonin-noradrenaline reuptake inhibitor that is effective for long-term weight reduction and maintenance in obese patients when used as an adjunct to dietary and behavioural measures. "( Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Cutler, NR; Leibowitz, MT; Levy, B; McMahon, FG; Mendel, CM; Mullican, WS; Rowe, ED; Sramek, JJ; Toth, PD; Weinstein, SP, 2002
)
2.07
"Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet. "( The discovery and status of sibutramine as an anti-obesity drug.
Luque, CA; Rey, JA, 2002
)
2.05
"Sibutramine HCl is an inhibitor of the reuptake of monoamines with a pharmacological profile in rodents indicative of antidepressant activity. "( The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride.
Buckett, WR; Hopcroft, RH; Luscombe, GP; Thomas, PC, 1989
)
1.92
"If sibutramine proves to be an effective antidepressant it should be devoid of anticholinergic or central depressant effects."( Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers.
Devaney, N; King, DJ, 1988
)
1.09

Effects

Sibutramine has been described as an anti-obesity drug with the ability to inhibit serotonin (5-HT), noradrenaline, and dopamine re-uptake. It has been shown to exert favorable effects on some surrogate cardiovascular endpoints such as reduction of left ventricular hypertrophy.

ExcerptReferenceRelevance
"Sibutramine has a dual mode of action. "( Sibutramine: its mode of action and efficacy.
Finer, N, 2002
)
3.2
"Sibutramine use has been associated with numerous adverse events in particular cardiovascular complications possibly due to the formation of thrombi."( The effect of sibutramine, a serotonin-norepinephrine reuptake inhibitor, on platelets and fibrin networks of male Sprague-Dawley rats: a descriptive study.
Bester, MJ; Oberholzer, HM; van der Schoor, C; van Rooy, MJ, 2014
)
1.48
"Sibutramine has been withdrawn in Europe but is still available on the Internet and is a component in some slimming preparations."( Antiobesity drugs in early pregnancy and congenital malformations in the offspring.
Källén, BA,
)
0.85
"Sibutramine use has raised concerns regarding a potential increase in subjects' blood pressure and heart rate."( Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients.
Elisaf, MS; Filippatos, TD; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP; Nakou, E; Tselepis, AD, 2008
)
1.46
"Sibutramine has conflicting effects on blood pressure: in some studies there was a minimal decrease, in some others a modest increase."( [Pharmacological therapy of obesity].
Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V, 2008
)
1.07
"Sibutramine has been more effective than Rimonabant and Control groups by decreasing the blood glycemia."( Comparison of rimonabant and sibutramine treatment effects on food compulsion in rats.
Camargo, PS; Ciulla, V; Correa, CA; Menezes, HS; Oliveira, TM,
)
1.14
"Sibutramine has been shown to exert favorable effects on some surrogate cardiovascular endpoints such as reduction of left ventricular hypertrophy and improvement of endothelial dysfunction."( Cardiovascular risk-benefit profile of sibutramine.
Scheen, AJ, 2010
)
1.35
"Sibutramine has a dual mode of action. "( Sibutramine: its mode of action and efficacy.
Finer, N, 2002
)
3.2
"Sibutramine has actions on both energy intake and expenditure and had been shown to enhance weight loss and weight maintenance achieved by diet, in simple obesity as well as when accompanied by complications of diabetes or hypertension."( Pharmacotherapy of obesity.
Finer, N, 2002
)
1.04
"Sibutramine has demonstrated efficacy in reducing weight in non-diabetic women along with amelioration in insulin sensitivity and additional improvement in metabolic parameters."( Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial.
Geloneze, B; Geloneze, SR; Magro, DO; Picolo, M; Repetto, EM; Tambascia, MA, 2003
)
3.2
"Sibutramine has also been studied in a number of unique populations, including obese controlled hypertensives, diabetics and ethnic minorities, further establishing its effectiveness."( Sibutramine and the management of obesity.
Foreyt, JP; Poston, WS, 2004
)
2.49
"Both sibutramine and ephedrine have been shown to have weight loss potential, however, they elicit different metabolic and biochemical responses after a single dose. "( Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers.
Balderson, DE; Brouwer, KL; Lancaster, ME; Ng, C; Paulik, MA; Persky, AM; Song, MH, 2004
)
1.06
"Sibutramine has been shown to be effective and safe as an adjuvant therapy to diet restrictions."( Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity.
Afriat, R; Bortnik, O; Goldman, M; Reisler, G; Tauber, T, 2006
)
2.5
"Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension."( The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea.
Banerjee, D; Caterson, I; Grunstein, RR; Hedner, JA; Phillips, CL; Yee, BJ, 2007
)
1.42
"Sibutramine hydrochloride has nearly no effect on the serum protein conformation."( [Spectroscopic studies on the binding of sibutramine hydrochloride and bovine serum albumin].
Chen, CY; Long, Q; Lu, Y; Xiang, BR, 2006
)
1.32
"Sibutramine has been described as an anti-obesity drug with the ability to inhibit serotonin (5-HT), noradrenaline, and dopamine re-uptake, but without affinity to histamine and muscarinic receptors. "( Locomotor and peripheral effects of sibutramine modulated by 5-HT2 receptors.
Brum, C; Della Santa Rubio, A; Frassetto, SS; Khazzaka, M; Lopes, JJ; Pereira, P; Vinagre, AS, 2006
)
2.05
"Sibutramine has also been evaluated for use in overweight adolescents in 6 trials."( Pharmacotherapeutic options for overweight adolescents.
Desilets, AR; Dunican, KC; Montalbano, JK, 2007
)
1.06
"Sibutramine has also been proven effective in reducing weight in this population; however, the potential for severe adverse effects requires further investigation."( Pharmacotherapeutic options for overweight adolescents.
Desilets, AR; Dunican, KC; Montalbano, JK, 2007
)
1.06
"Sibutramine has been relatively under-utilised by Maori and Pacific ethnic groups, compared to New Zealand Europeans, despite their higher prevalence of obesity."( Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme.
Ashton, J; Harrison-Woolrych, M; Hill, GR, 2007
)
2.5
"Sibutramine has been shown to decrease food intake in the rat."( Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat.
Bearham, MC; Heal, DJ; Hutchins, LJ; Jackson, HC; Mazurkiewicz, SE; Needham, AM, 1997
)
1.23
"Sibutramine has also been shown to substantially increase blood pressure and heart rate in some patients."( Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.
Luque, CA; Rey, JA, 1999
)
2.47

Actions

Sibutramine caused an increase in blood pressure (both SBP and DBP) in two patients, but it has been controlled by antihypertensive treatment. The drug can increase blood pressure and heart rate, which may attenuate the reductions in LVM associated with weight loss.

ExcerptReferenceRelevance
"Sibutramine can increase blood pressure and heart rate, which may attenuate the reductions in LVM associated with weight loss."( Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
Boivin, JM; Bruntz, JF; Drouin, P; Gille, B; Grentzinger, A; Hammadi, M; Hanotin, C; Igau, B; Zannad, F, 2002
)
1.43
"Sibutramine can produce dose-dependent increases in blood pressure and heart rate, especially during initial treatment. "( Sibutramine and its cardiovascular profile.
Narkiewicz, K, 2002
)
3.2
"Sibutramine caused an increase in blood pres sure (both SBP and DBP) in one patient, but it was controlled by anti-hypertensive treatment."( Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Murdolo, G, 2004
)
1.3
"Sibutramine caused an increase in blood pressure (both SBP and DBP) in two patients, but it has been controlled by antihypertensive treatment."( Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Murdolo, G; Piccinni, MN, 2005
)
1.29
"The sibutramine-induced increase in EE was accompanied by an increase in plasma epinephrine (P < 0.01), heart rate (P < 0.001), blood pressure (P < 0.05), and plasma glucose (P < 0.02)."( Thermogenic effects of sibutramine in humans.
Astrup, A; Hansen, DL; Macdonald, IA; Stock, MJ; Toubro, S, 1998
)
1.09
"2. Sibutramine induced an increase in extracellular noradrenaline concentration, the magnitude of which paralleled dose, in both brain areas."( Modulation of sibutramine-induced increases in extracellular noradrenaline concentration in rat frontal cortex and hypothalamus by alpha2-adrenoceptors.
Heal, DJ; Stanford, SC; Wortley, KE, 1999
)
1.18

Treatment

Sibutramine treatment decreased final body and reproductive organ weights, as well as serum testosterone levels. The drug raised sitting diastolic blood pressure by > or = 5 mmHg in a higher proportion of patients than did placebo.

ExcerptReferenceRelevance
"Sibutramine treatment decreased final body and reproductive organ weights, as well as serum testosterone levels."( Impact of timing of the anorexigen sibutramine administration on reproductive end-points of male rats.
Anselmo-Franci, JA; Borges, CS; Kempinas, WG; Lozano, AFQ; Missassi, G; Silva, PV; Silva, RF, 2020
)
1.56
"For sibutramine, higher on-treatment elevations in SBP (1.6; -1.3, 4.5 vs."( Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
Johansson, K; Neovius, K; Neovius, M; Rössner, S; Sundström, J, 2010
)
1.08
"Sibutramine treatment causes a reduction in total neuropeptide YY3-36, systemic metabolism, and adipose tissue at the expense of the visceral depot."( [Effect of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity].
Ametov, AS; Vlasova, IuIu, 2010
)
1.47
"Sibutramine treatment raised sitting diastolic blood pressure by > or = 5 mmHg in a higher proportion of patients than did placebo (43% with 15 mg/day vs."( A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.
McNulty, SJ; Ur, E; Williams, G, 2003
)
1.35
"Sibutramine treatment significantly increased resting metabolic rate compared to the placebo condition. "( Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers.
Balderson, DE; Brouwer, KL; Lancaster, ME; Ng, C; Paulik, MA; Persky, AM; Song, MH, 2004
)
1.99
"Sibutramine treatment reduced body mass index (P < 0.05) and total body fat (P < 0.05)."( Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women.
Ahn, CW; Cha, BS; Huh, KB; Kim, DM; Kim, KR; Lee, HC; Lim, SK; Yoon, SJ, 2004
)
2.49
"Sibutramine treatment caused a slight increase in supine HR that was sustained throughout the studies."( Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials.
Hauner, H; Jordan, J; Matiba, B; Scholze, J; Sharma, AM; Wirth, A, 2005
)
1.42
"Sibutramine treatment is unlikely to elicit a critical increase in blood pressure even in hypertensive patients. "( Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials.
Hauner, H; Jordan, J; Matiba, B; Scholze, J; Sharma, AM; Wirth, A, 2005
)
2.14
"Sibutramine treatment profoundly and selectively reduces sympathetic nerve traffic at rest and attenuates the responsiveness to sympathetic stimuli. "( Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects.
Diedrich, A; Engeli, S; Heusser, K; Jordan, J; Klaua, S; Krüger, N; Luft, FC; Stoffels, G; Strauss, A; Tank, J, 2006
)
2.15
"Sibutramine treatment did not show significant weight loss compared with placebo in clozapine-treated patients with schizophrenia or schizoaffective disorder. "( A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Nguyen, DD; Zhang, H, 2007
)
2.04
"Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment."( Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007
)
1.29
"Sibutramine treatment resulted in significant decreases in apolipoprotein B, apolipoprotein B/apolipoprotein A ratio, triglycerides, and cystatin C levels."( Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Bixo, M; Björn, I; Eliasson, M; Johnson, O; Larsson, A; Lindholm, Å; Poromaa, IS; Wölner-Hanssen, P, 2008
)
1.47
"The sibutramine-treated group achieved 2.0 kg (2.5%) weight loss with observable but not statistically significant changes in insulin sensitivity, glycemic control, and cardiovascular risk factors. "( Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
Chen, CH; Chou, KM; Fanchiang, JK; Huang, BY,
)
0.98
"Sibutramine treatment did not affect the dietary behaviour of high-protein- or high-carbohydrate-fed rats, while it significantly attenuated the daily food intake and body weight gain rate in the high-fat group, at the dose of 10 mg/kg."( Effect of isocaloric diets and sibutramine on food intake, body mass variation and serum TNF-alpha levels in rats.
Couvari, E; Dontas, I; Galanopoulou, P; Liapi, C; Mavri, M; Perelas, A; Perrea, D; Stroubini, T; Trapali, M, 2008
)
1.35
"Sibutramine treatment decreased body weight gain by 12% without a significant overall change in daily food intake. "( Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice.
Bailey, CJ; Day, C, 1998
)
2.03
"Sibutramine-treated patients had small but statistically significant mean increases in diastolic blood pressure (2.0 mm Hg) and pulse rate (4.9 beats/min) compared with placebo-treated patients (-1.3 mm Hg and 0.0 beats/min; P<.05); these changes were similar among African Americans and whites."( Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
Fujioka, K; Johnson, F; McMahon, FG; Mendel, CM; Mooradian, AD; Rolston, K; Rowe, E; Singh, BN, 2000
)
1.34
"Sibutramine treatment increased sympathetic activity, attenuated the increased ARC NPY, and decreased POMC mRNA levels induced by energy restriction in RV rats."( Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats.
Dunn-Meynell, AA; Levin, BE, 2000
)
2.47
"Sibutramine treatment was associated with small mean increases in blood pressure (BP) and pulse, although an increase in BP was not seen in sibutramine-treated patients who lost > or = 5% of their weight."( Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
Fujioka, K; Jelinek, CA; Lebovitz, HE; Raskin, P; Rowe, E; Seaton, TB; Weinstein, SP, 2000
)
1.37
"Sibutramine treatment in obesity results in significantly greater weight reduction compared with placebo, although weight loss with sibutramine may be accompanied by small but statistically significant mean increases in blood pressure (BP). "( Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
Ernst, KR; Fujioka, K; Johnson, F; McMahon, FG; Rowe, E; Weinstein, SP, 2002
)
3.2
"Treatment with sibutramine provoked HASM cell apoptosis, which was attributed to production of reactive oxygen species and mitochondria dysfunction."( Sibutramine facilitates apoptosis and contraction of aortic smooth muscle cells through elevating production of reactive oxygen species.
Endo, S; Ikari, A; Matsunaga, T; Morikawa, Y; Sasajima, Y; Sato, K; Shibata, A; Suenami, K; Takekoshi, Y, 2018
)
2.26
"Treatment with sibutramine also resulted in significantly greater reduction of body fat for specific alpha2A CC and GNbeta3 TC/TT genotype variants individually (both P < .02)."( A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.
Braddock, AE; Burton, DD; Camilleri, M; Carlson, PJ; Clark, MM; Eckert, DJ; Graszer, KM; Grudell, AB; Kalsy, SA; Sweetser, S; Vazquez-Roque, MI; Zinsmeister, AR, 2008
)
0.96
"Treatment with sibutramine or orlistat is not cost-effective from an Australian health sector perspective and has a negligible impact on the total body weight-related disease burden."( Cost-effectiveness of pharmacotherapy to reduce obesity.
Barendregt, JJ; Forster, M; Veerman, JL; Vos, T, 2011
)
0.72
"Treatment with sibutramine significantly reduces the body weight and leptin, increases insulin senstivity, and improves IR."( [Serum leptin and insulin resistance in obesity and effects of sibutramine on them].
Chen, HL; Lei, MX; Wu, J, 2003
)
0.9
"Treatment with sibutramine plus behavioral therapy did not induce sexual dysfunction and sibutramine-induced weight reduction appeared to have a positive impact on sexual function in this small group of overweight and moderately obese women. "( Influence of weight reduction by sibutramine on female sexual function.
Kang, HC; Kim, KK; Kim, SS; Youn, BB, 2006
)
0.97
"Treatment with sibutramine may be particularly efficient in these patients, because sibutramine normalizes sympathoadrenal activity and thereby stimulates thermogenesis."( [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
Astrup, A, 1998
)
1.55
"Treatment with sibutramine at 3 and 10 mg/kg p.o."( Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines.
Gomita, Y; Nakagawa, T; Ohyama, T; Okamura, H; Ukai, K, 2000
)
0.92
"Treatment with sibutramine, 15 mg/day, was administered for 12 weeks."( An open-label trial of sibutramine in obese patients with binge-eating disorder.
Appolinario, JC; Cabral, M; Carraro, L; Coutinho, W; Fontenelle, LF; Godoy-Matos, A; Vieira, A, 2002
)
0.96

Toxicity

Sibutramine of the dosage of 10 mg/day is an effective and safe therapy for weight reduction in obese subjects. Most adverse events were mild or moderate in severity. The incidence of adverse effects was similar for sibuthamine and placebo, except for tachycardia.

ExcerptReferenceRelevance
" A multifaceted approach to the obese patient should include identifying potential causes for weight gain, outlining medical conditions that would benefit by weight loss, and tailoring a weight loss program that is safe and effective for the individual."( Safe and effective management of the obese patient.
Collazo-Clavell, ML, 1999
)
0.3
" Safety assessments included recording of blood pressure, pulse rate, adverse events, and reasons for discontinuation."( Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
Fujioka, K; Johnson, F; McMahon, FG; Mendel, CM; Mooradian, AD; Rolston, K; Rowe, E; Singh, BN, 2000
)
0.62
" Most adverse events were mild to moderate in severity and transient."( Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
Fujioka, K; Johnson, F; McMahon, FG; Mendel, CM; Mooradian, AD; Rolston, K; Rowe, E; Singh, BN, 2000
)
0.62
" Sibutramine was well tolerated, and most adverse events were mild or moderate in severity."( Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Cutler, NR; Leibowitz, MT; Levy, B; McMahon, FG; Mendel, CM; Mullican, WS; Rowe, ED; Sramek, JJ; Toth, PD; Weinstein, SP, 2002
)
1.54
"The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females."( Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002
)
0.85
" In the sibutramine group, 14 patients reported 21 adverse events, most frequently headache (n=5), constipation (n=4), and dry mouth (n=4)."( Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension.
Berber, A; Campos-Franco, E; Cortinas, L; Fanghänel, G; Gómez-Santos, R; Sánchez-Reyes, L,
)
0.88
" The incidence of adverse events was 35."( [A multicenter and open study on efficacy and safety of sibutramine in obese subjects].
Ning, G, 2004
)
0.57
"Sibutramine of the dosage of 10 mg/day is an effective and safe therapy for weight reduction in obese subjects."( [A multicenter and open study on efficacy and safety of sibutramine in obese subjects].
Ning, G, 2004
)
2.01
" Side-effect profiles were different in the two treatment groups."( Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Murdolo, G; Piccinni, MN, 2005
)
0.57
" The main outcome measures were changes in body weight, blood pressure and heart rate, and evaluation of reported adverse events."( Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
Gaciong, Z; Placha, G, 2005
)
0.64
" These potentially adverse effects as well as other sibutramine-associated side effects and their possible underlying mechanisms are reviewed in the present article."( Sibutramine-associated adverse effects: a practical guide for its safe use.
Elisaf, MS; Florentin, M; Liberopoulos, EN, 2008
)
2.04
" Adverse events reported as case reports were also evaluated to determine whether these events were also identified by PEM."( The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
Perrio, MJ; Shakir, SA; Wilton, LV, 2007
)
0.61
" Patient demographic and clinical event information, including reasons for stopping and adverse drug reactions, were requested on questionnaires posted to GPs at least 6 months after the first prescription for individual patients."( The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
Perrio, MJ; Shakir, SA; Wilton, LV, 2007
)
0.61
"The PEM studies highlighted different adverse event profiles for orlistat and sibutramine that were consistent with their distinct pharmacological mechanisms and other published information."( The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
Perrio, MJ; Shakir, SA; Wilton, LV, 2007
)
0.84
"The objective of this article was to estimate the risk of discontinuation due to adverse events in trials of orlistat, sibutramine and rimonabant."( Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
DeSantis, SM; Johansson, K; Neovius, K; Neovius, M; Rössner, S, 2009
)
0.79
"24 SD) with a high prevalence of gastrointestinal adverse effects."( Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
Hsia, Y; Tomsic, T; Viner, RM; Wong, IC, 2010
)
0.36
"To provide a systematic review of the best evidence about the effect of sibutramine and orlistat in weight loss, quality of life and its adverse effects in adolescents diagnosed with obesity."( Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
García Díaz, E; Martín Folgueras, T,
)
0.62
" The incidence of adverse effects was similar for sibutramine and placebo, except for tachycardia."( Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
García Díaz, E; Martín Folgueras, T,
)
0.64
" We analyzed toxic and trace element levels of nine herbal products and found that these herbal products, even in low amounts, contain Pb, Al, Ni, and Ba."( How safe is the use of herbal weight-loss products sold over the internet?
Celbis, O; Erdogan, S; Kapucu, H; Karakoc, Y; Onal, Y; Ozdemir, B; Sahin, I, 2013
)
0.39
" Moreover, they also may become contaminated with toxic metals."( How safe is the use of herbal weight-loss products sold over the internet?
Celbis, O; Erdogan, S; Kapucu, H; Karakoc, Y; Onal, Y; Ozdemir, B; Sahin, I, 2013
)
0.39

Pharmacokinetics

Clopidogrel significantly increased the half-life (242% of control phase) and area under the plasma concentration-time curve from 0 to infinity (AUC(inf) of sibutramine. A statistically significant difference in the elimination half- life (t(1/2) of Sibutamine M1 was found among the 3 genotype groups (P = .

ExcerptReferenceRelevance
" Model-independent pharmacokinetic parameters of the two metabolites were compared for the two age groups."( Sibutramine pharmacokinetics in young and elderly healthy subjects.
Garratt, CJ; Ghani, SP; Haddock, RE; Hind, ID; Jones, RW; Mangham, JE, 1999
)
1.75
"To evaluate the pharmacokinetic profiles of the pharmacologically active primary amine metabolite of sibutramine, N-di-desmethyl sibutramine (BTS 54505) in Chinese origin."( Pharmacokinetics of sibutramine hydrochloride in Chinese healthy volunteers.
Chen, HZ; Chen, J; Huang, X; Jiang, XG; Lu, W; Rong, ZX, 2003
)
0.86
"Various pharmacokinetic parameters including AUC0-t, AUC0-infinity, Cmax, Tmax, T1/2, Kelm and MRT were determined for both test and reference capsules and found to be in good agreement with literature values."( Pharmacokinetics of sibutramine hydrochloride in Chinese healthy volunteers.
Chen, HZ; Chen, J; Huang, X; Jiang, XG; Lu, W; Rong, ZX, 2003
)
0.64
" The objective of the present study was to compare the pharmacodynamic responses of ephedrine and sibutramine using surrogate markers of weight loss potential and potential adverse events."( Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers.
Balderson, DE; Brouwer, KL; Lancaster, ME; Ng, C; Paulik, MA; Persky, AM; Song, MH, 2004
)
0.76
" Healthy, mildly overweight (BMI = 25) subjects were administered the respective treatment and pharmacokinetic and pharmacodynamic measurements (body surface temperature, resting metabolic rate, blood pressure, heart rate, glucose, glycerol, nonesterified fatty acids, triglycerides) were obtained for 8 hours post dose and for an additional 4 measurements during the sibutramine treatment period."( Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers.
Balderson, DE; Brouwer, KL; Lancaster, ME; Ng, C; Paulik, MA; Persky, AM; Song, MH, 2004
)
0.72
" Blood samples for pharmacokinetic analysis were collected during a 72-hour period after treatment."( Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study.
Kim, KA; Lee, GS; Park, JY; Park, PW; Suh, KH, 2004
)
0.57
" The reference and test formulations showed pharmacokinetic equivalence with respect to M1 and M2."( Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study.
Kim, KA; Lee, GS; Park, JY; Park, PW; Suh, KH, 2004
)
0.57
" A statistically significant difference in the elimination half-life (t(1/2)) of sibutramine M1 was found among the 3 genotype groups (P = ."( Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects.
Chung, JY; Jang, SB; Lee, YJ; Park, K; Park, MS, 2011
)
0.85
" Clopidogrel significantly increased the half-life (242% of control phase) and area under the plasma concentration-time curve from 0 to infinity (AUC(inf)) (227% of control phase) of sibutramine and decreased the apparent oral clearance (31% of control phase) of sibutramine."( Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites.
Bae, JW; Jang, CG; Lee, SY, 2011
)
0.81
" The validated method was successfully applied to a pharmacokinetic study in human."( Simultaneous determination of sibutramine and its active metabolites in human plasma by LC-MS/MS and its application to a pharmacokinetic study.
Bae, JW; Choi, CI; Jang, CG; Lee, SY, 2011
)
0.66

Compound-Compound Interactions

Electric-heat needle combined with acupoint stic-king therapy has better therapeutic effect on simple obesity of spleen deficiency.

ExcerptReferenceRelevance
" In this study, we aimed to assess the effect of low-dose cardio-selective beta blocker combination with sibutramine treatment."( Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study.
Baykan, M; Durmus, I; Erem, C; Ersoz, HO; Hacihasanoglu, A; Telatar, M; Ukinc, K, 2004
)
0.79
" In addition, the Y5 antagonist combined with either food restriction or sibutramine tended to produce greater body weight loss, as compared with single treatment."( Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
Fukami, T; Gomori, A; Ishihara, A; Ito, J; Iwaasa, H; Kanatani, A; Kitazawa, H; MacNeil, DJ; Mashiko, S; Matsushita, H; Mitobe, Y; Moriya, R; Takahashi, T; Van der Ploeg, LH, 2008
)
0.8
"To observe clinical effect differences between electric-heat needle combined with acupoint sticking therapy and oral administration of western medicine for treatment of simple obesity of spleen deficiency and dampness stagnation type."( [Clinical observation on therapeutic effect of electric-heat needle combined with acupoint sticking therapy for treatment of simple obesity].
Li, B; Song, P; Zhang, FX; Zhang, P; Zhu, Y, 2010
)
0.36
"The electric-heat needle combined with acupoint sticking therapy group (n=80) was treated with acupuncture at Daimai (GB 26), Zhongwan (CV 12), Zusanli (ST 36), etc."( [Clinical observation on therapeutic effect of electric-heat needle combined with acupoint sticking therapy for treatment of simple obesity].
Li, B; Song, P; Zhang, FX; Zhang, P; Zhu, Y, 2010
)
0.36
"5% (78/80) in the electric-heat needle combined with acupoint sticking therapy group and 70."( [Clinical observation on therapeutic effect of electric-heat needle combined with acupoint sticking therapy for treatment of simple obesity].
Li, B; Song, P; Zhang, FX; Zhang, P; Zhu, Y, 2010
)
0.36
"Electric-heat needle combined with acupoint stic-king therapy has better therapeutic effect on simple obesity of spleen deficiency and dampness stagnation type than that of oral administration of Sibutramine Hydrochloride capsules."( [Clinical observation on therapeutic effect of electric-heat needle combined with acupoint sticking therapy for treatment of simple obesity].
Li, B; Song, P; Zhang, FX; Zhang, P; Zhu, Y, 2010
)
0.55
" The results of FTIR spectra combined with DFT calculations permitted identification of the bands corresponding to the dynamics and vibrations of water molecules."( Calorimetric, FTIR and 1H NMR measurements in combination with DFT calculations for monitoring solid-state changes of dynamics of sibutramine hydrochloride.
Chudoba, DM; Mielcarek, J; Pajzderska, A; Wąsicki, J, 2012
)
0.58

Bioavailability

This study was conducted to compare the relative bioavailability and pharmacokinetics of the new sibutramine formulation (test) with those of the conventional formulation (reference) Following oral ingestion, sibutsramine is well absorbed and undergoes extensive first pass metabolism. The absolute bioavailability of sibotsramine was only about 7%.

ExcerptReferenceRelevance
" Following oral ingestion, sibutramine is well absorbed and undergoes extensive first pass metabolism."( Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
De Leeuw, IH; Van Gaal, LF; Wauters, MA, 1998
)
0.89
" In contrast with what is reported in the product monograph, this study demonstrated that the bioavailability of sibutramine and M1 metabolite was significantly increased with administration with food."( A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions.
Abolfathi, Z; Couture, J; LeBel, M; Masson, E; Tanguay, M; Vallée, F, 2004
)
0.79
" Drugs formed from different salts may differ in their solubility profiles and dissolution rates, which may affect their rate of absorption and thus their onset, duration, and intensity of effect."( Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study.
Kim, KA; Lee, GS; Park, JY; Park, PW; Suh, KH, 2004
)
0.57
"This study was conducted to compare the relative bioavailability and pharmacokinetics of the new sibutramine formulation (test) with those of the conventional formulation (reference)."( Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study.
Kim, KA; Lee, GS; Park, JY; Park, PW; Suh, KH, 2004
)
0.79
" The relative bioavailability of the test drug was 117."( Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study.
Kim, KA; Lee, GS; Park, JY; Park, PW; Suh, KH, 2004
)
0.57
"This study was conducted in order to compare the bioavailability of two capsule formulations containing 15 mg of sibutramine, N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine hydrochloride monohydrate, 84485-00-7 CAS registry number."( Comparative bioavailability of two formulations of sibutramine.
Abolfathi, Z; Almeida, S; Anctil, D; Filipe, A; Franco Spínola, AC; Neves, R; Yritia, M, 2009
)
0.82
" The absolute bioavailability of sibutramine was only about 7%."( Enantioselective pharmacokinetics of sibutramine in rat.
Bae, K; Jeong, T; Kang, W; Kim, E; Kwon, KI; Min, B; Noh, K, 2010
)
0.91
" Thus, the sibutramine base-loaded solid dispersion prepared with gelatin, HPMC and citric acid is a promising candidate for improving the solubility and bioavailability of the poorly water-soluble sibutramine base."( Development of novel sibutramine base-loaded solid dispersion with gelatin and HPMC: physicochemical characterization and pharmacokinetics in beagle dogs.
Balakrishnan, P; Choi, HG; Hwang, DH; Joe, KH; Kim, YR; Lee, YB; Lim, HT; Oh, DH; Yong, CS, 2010
)
1.07
" Screening of novel bicyclic motifs with high intrinsic binding affinity for MCHR1 identified the imidazo[1,2-a]pyridine ring (represented in compounds 6a and 6b), and subsequent cyclization of the central aliphatic amide linkage led to the discovery of a potent, orally bioavailable MCHR1 antagonist 4-[(4-chlorobenzyl)oxy]-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one 10a."( Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure-Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one Derivatives.
Aida, J; Ashina, S; Hirabayashi, H; Igawa, H; Ikoma, M; Kakegawa, K; Kasai, S; Kawata, Y; Khamrai, U; Kina, A; Kundu, M; Maekawa, T; Nagisa, Y; Nakayama, M; Takahashi, M; Yamamoto, S; Yasuma, T, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Sibutramine was effective at promoting minimum beneficial BMI reduction of 5% in adolescents with service-connected parents. After four weeks this treatment could be continued, terminated or increased to a dosage of 15 mg sibuthamine per day.

ExcerptRelevanceReference
" Chronic dosage studies are indicated to evaluate the clinical significance of its cardiovascular effects."( Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers.
Devaney, N; King, DJ, 1988
)
0.58
"), shifted the dose-response relationships to the right for each of the antidepressant agents (dothiepin, amitriptyline, sibutramine, (+)-oxaprotiline and paroxetine)."( The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds.
Gray, AM; Sewell, RD; Spencer, PS, 1998
)
0.51
" Concerns over potential pressor effects with sibutramine are reflected in the manufacturer's dosage and administration recommendations."( Sibutramine. A review of its contribution to the management of obesity.
Goa, KL; McNeely, W, 1998
)
2
" Based on this information, a similar dosing regimen would be appropriate for both the young and elderly."( Sibutramine pharmacokinetics in young and elderly healthy subjects.
Garratt, CJ; Ghani, SP; Haddock, RE; Hind, ID; Jones, RW; Mangham, JE, 1999
)
1.75
"05) across all time-points for a 5 mg/day to 30 mg/day dosage of sibutramine."( Sibutramine produces dose-related weight loss.
Blackburn, GL; Bray, GA; Ferguson, JM; Greenway, FL; Jain, AK; Mendel, CM; Mendels, J; Ryan, DH; Scheinbaum, ML; Schwartz, SL; Seaton, TB, 1999
)
1.98
" Sibutramine, when dosed alone, was associated with improved performance on several tasks."( Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers.
Garratt, C; Gudgeon, A; Oliver, S; Wesnes, KA; Wickens, M, 2000
)
1.61
") using the same dosing regimen as described above."( Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine.
Cheetham, SC; Heal, DJ; Slater, NA; Viggers, JA, 2000
)
1.75
" To achieve moderate calorie restriction (deficit > or = 250-500 kcal/day), individual dietary counselling was accompanied by either placebo or sibutramine (initial dosage of 5 mg/day titrated up by 5 mg biweekly through week 6, and maintained at 20 mg through week 24)."( Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
Fujioka, K; Jelinek, CA; Lebovitz, HE; Raskin, P; Rowe, E; Seaton, TB; Weinstein, SP, 2000
)
0.85
" After four weeks this treatment could be continued, terminated or increased to a dosage of 15 mg sibutramine per day."( [Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters].
Scholze, J, 2002
)
1.44
"Lean and obese Zucker rats were orally dosed with SR 141716 (3, 10, 30 mg/kg PO), sibutramine (5 mg/kg PO) or vehicle for one week."( Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.
Dourish, CT; Kennett, GA; Vickers, SP; Webster, LJ; Wyatt, A, 2003
)
0.54
" This involved two 4-week dosing periods separated by a 2-week washout."( Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm.
Burgard, MA; Crosby, RD; de Zwaan, M; Gosnell, BA; Mitchell, JE; Roerig, JL; Wambach, BN; Wonderlich, SA, 2003
)
0.71
" By subgroup analysis, the effect sizes on weight loss were significantly larger when the dosage was > or = 15 mg."( Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.
Jee, SH; Kim, SH; Lee, YM; Nam, CM, 2003
)
0.72
" The most frequent dosage regimen in these trials was 10-20 mg daily."( A benefit-risk assessment of sibutramine in the management of obesity.
Carruba, MO; Nisoli, E, 2003
)
0.61
" In conclusion, sibutramine affected macronutrient selection and emphasis on dietary recommendations, as well as appropriate dosage according to gender should be considered during therapy."( Effect of sibutramine on macronutrient selection in male and female rats.
LeBlanc, M; Thibault, L, 2003
)
1.07
"Sibutramine of the dosage of 10 mg/day is an effective and safe therapy for weight reduction in obese subjects."( [A multicenter and open study on efficacy and safety of sibutramine in obese subjects].
Ning, G, 2004
)
2.01
" Of this overall study group, 47 patients (26 with normoten-sion and 21 with controlled hypertension) received sibu-tramine in a dosage of 10 mg/day, and 34 patients (18 with normotension and 16 with controlled hypertension) received sibutramine in a dosage of 15 mg/day."( Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension.
Başkal, N; Cesur, M; Cin, MO; Erdoğan, MF; Gürsoy, A,
)
0.72
" Moreover, the mean HR did not change significantly after versus before sibutramine treatment in both dosage groups."( Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension.
Başkal, N; Cesur, M; Cin, MO; Erdoğan, MF; Gürsoy, A,
)
0.77
" They started with a dosage of 1 capsule per day, gradually increasing the Meizitanc dose to 3 capsules a day."( [Side effects after the usage of Chinese dieting product Meizitanc].
Chodorowski, Z; Sein Anand, J, 2007
)
0.34
" The effects of 7 days dosing with sibutramine 10 mg and 15 mg a day on appetite and energy balance were determined in 30 obese women (BMI 34."( The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women.
Boyland, EJ; Cooper, SJ; Dawson, GR; Dourish, CT; Dovey, TM; Halford, JC; Huda, MS; Wilding, JP, 2010
)
0.99
"A 39-year-old white woman started to take sibutramine to lose weight at a dosage of 10 mg/day."( Sibutramine-associated psychosis (case report).
Gazdag, G; Szabó, Z, 2008
)
2.05
" Single dosing with sibutramine (3."( Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats.
Blundell, JE; Rodgers, RJ; Tallett, AJ, 2009
)
2.12
"Five hundred and seventy-six consecutive Caucasian obese type 2 diabetic patients were evaluated during a 12-months period and fifty-two patients were resulted intolerant to metformin at maximum dosage (3,000 mg/day)."( Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Piccinni, MN; Salvadeo, SA, 2009
)
0.58
" One hour after the last dosing of clopidogrel, all subjects received 15-mg of sibutramine."( Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites.
Bae, JW; Jang, CG; Lee, SY, 2011
)
0.85
"Sibutramine was effective at promoting minimum beneficial BMI reduction of 5% in adolescents with service-connected parents; however, increasing dosage at 3 months did not improve the likelihood of being successful."( Multidisciplinary intervention with sibutramine: assessing successful weight loss predictors in military adolescent dependents.
Blankson, KL; Cabrera, JL; Cole, RE; Symons, JE; Wilks, EG, 2012
)
2.1
" The model could also be used to assess dose-response relationships."( Assessment of maximum weight change and duration of therapeutic effect for non-surgical treatment of obesity using an exponential model.
Chan, LS; Kaptein, EM; Kaptein, JS, 2012
)
0.38
" The first group received three daily 120 mg dosages of orlistat for nine months (n=39), and the second group received a once daily 10 or 15 mg dosage of sibutramine for nine months (n=37)."( Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects.
Al-Safi Ismail, AA; Al-Tahami, BAM; Rasool, AHG; Sanip, Z; Shihabudin, TMT; Singh, TSP; Yusoff, Z, 2017
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anti-obesity agentAny substance which is used to reduce or control weight.
serotonin uptake inhibitorA compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
PPM1D proteinHomo sapiens (human)Potency32.99930.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
EWS/FLI fusion proteinHomo sapiens (human)Potency27.12170.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency0.00460.004611.374133.4983AID624296
VprHuman immunodeficiency virus 1Potency31.62281.584919.626463.0957AID651644
Interferon betaHomo sapiens (human)Potency32.99930.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)5.66500.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki5.61900.00322.28879.3160AID625207
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)2.39000.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki1.09100.00020.725710.0000AID625202
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)5.66500.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki5.61900.00031.465610.0000AID625207
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)2.08500.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki1.10800.00000.70488.1930AID625222
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)0.63200.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki0.50200.00021.11158.0280AID625256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (101)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (85)

Assay IDTitleYearJournalArticle
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID443392Reduction in food intake in diet-induced obese Wistar rat chronic feeding model at 6 mg/kg, po once daily measured after 14 days2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID480082Antiobese activity in high fat diet-fed Sprague-Dawley rat assessed as plasma triglyceride level at 10 mg/kg, ig administered QD for 30 days (Rvb = 1.25+/-0.23 mmol/L)2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities.
AID480078Antiobese activity in high fat diet-fed Sprague-Dawley rat assessed as body weight at 10 mg/kg, ig administered QD for 30 days (Rvb = 355+/-36 g)2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID547621Cytotoxicity against BESM cells after 88 hrs by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID270774Weigt loss in diet-induced obese AKR/J mouse at 3 mg/kg relative to control2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
The discovery and optimization of pyrimidinone-containing MCH R1 antagonists.
AID480080Antiobese activity in high fat diet-fed Sprague-Dawley rat assessed as body fat mass measured per 100 g of body weight at 10 mg/kg, ig administered QD for 30 days (Rvb = 6.4+/-1.4 g/100 g)2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities.
AID547804Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID480084Antiobese activity in high fat diet-fed Sprague-Dawley rat assessed as plasma total cholesterol level at 10 mg/kg, ig administered QD for 30 days (Rvb = 1.86+/-0.31 mmol/L)2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1238438Antiobesity activity in diet-induced obese Wistar rat model assessed as reduction of body weight at 5 mg/kg, po qd after 4 weeks2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908.
AID1280825Antiobesity activity in diet-induced obese F344/jcl rat assessed as reduction in body weight at 1 mg/kg, po qd administered through repeated dosing for 2 weeks measured during 2 weeks of dosing relative to vehicle-treated control2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure-Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one Derivatives.
AID1280824Anorectic activity in diet-induced obese F344/jcl rat assessed as inhibition of cumulative food intake at 1 mg/kg, po qd administered through repeated dosing for 2 weeks measured during 2 weeks of dosing relative to vehicle-treated control2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure-Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one Derivatives.
AID1295376Antiobesity activity in DIO-F344/Jcl rat assessed as reduction in body weight at 1 mg/kg, po dosed for 2 weeks and measured every 2 or 3 days relative to vehicle control2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition.
AID307533Reduction of cumulative food intake in over-night fasted mouse at 10 mg/kg, ip after 3 hrs relative to control2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design and synthesis of novel hydantoin-containing melanin-concentrating hormone receptor antagonists.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1295375Anorectic effect in DIO-F344/Jcl rat assessed as cumulative food intake at 1 mg/kg, po dosed for 2 weeks and measured every 2 or 3 days relative to vehicle control2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID661690Antiobesity activity in high-fat diet fed Fischer 344 rat DIO model assessed as inhibition of food intake at 1 mg/kg, po after 6 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Melanin-concentrating hormone receptor 1 antagonists. Synthesis and structure-activity relationships of novel 3-(aminomethyl)quinolines.
AID480086Antiobese activity in high fat diet-fed Sprague-Dawley rat assessed as plasma free fatty acid level at 10 mg/kg, ig administered QD for 30 days (Rvb = 785.6+/-175.8 umol/L)2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities.
AID661691Antiobesity activity in high-fat diet fed Fischer 344 rat DIO model assessed as inhibition of food intake at 1 mg/kg, po after 17 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Melanin-concentrating hormone receptor 1 antagonists. Synthesis and structure-activity relationships of novel 3-(aminomethyl)quinolines.
AID443391Reduction in food intake in diet-induced obese Wistar rat chronic feeding model at 6 mg/kg, po once daily after 8 days2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.
AID547622Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID661527Antiobesity activity in high fat diet-fed C57BL/6 mouse assessed as reduction in body weight at 3 mg/kg, po daily measured up to day 137 relative to control2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346716Rat Kv4.3 (Voltage-gated potassium channels)2007The Journal of pharmacology and experimental therapeutics, May, Volume: 321, Issue:2
Open channel block of A-type, kv4.3, and delayed rectifier K+ channels, Kv1.3 and Kv3.1, by sibutramine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (915)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (0.44)18.7374
1990's75 (8.20)18.2507
2000's554 (60.55)29.6817
2010's259 (28.31)24.3611
2020's23 (2.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.18 (24.57)
Research Supply Index7.08 (2.92)
Research Growth Index6.35 (4.65)
Search Engine Demand Index149.79 (26.88)
Search Engine Supply Index3.90 (0.95)

This Compound (48.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials218 (22.54%)5.53%
Reviews220 (22.75%)6.00%
Case Studies68 (7.03%)4.05%
Observational0 (0.00%)0.25%
Other461 (47.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (33)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Randomized, Double-blind, Double-dummy, Parallel-group, Active Drug and Placebo-controlled, Safety, Efficacy and Superiority of Sibutramine IR/Topiramate XR in Overweight Adults With Comorbidities/Obesity [NCT05209984]Phase 31,855 participants (Anticipated)Interventional2024-06-30Not yet recruiting
A Randomized, Double-blind, Placebo-controlled, Investigator-initiated Study to Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine [NCT01184560]174 participants (Actual)Interventional2010-02-28Completed
LY377604 + Sibutramine Hydrochloride Monohydrate: A Phase 2 Weight Loss Efficacy Study in Overweight/Obese Men and Women [NCT00993421]Phase 2343 participants (Actual)Interventional2009-10-31Terminated(stopped due to Clinical trial terminated due to results from recent nonclinical studies)
Randomized Trial of Obese Non-Diabetic Malaysians Using Sibutramine: A Randomized Double-Blind Placebo-Controlled Study of Sibutramine in the Management of Obese Subjects in Malaysia [NCT00677391]Phase 3103 participants (Actual)Interventional2002-12-31Completed
Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives [NCT00679653]Phase 3171 participants (Actual)Interventional2002-02-28Completed
Loss - Louisiana Obese Subjects Study [NCT00115063]Phase 4390 participants (Actual)Interventional2005-07-31Terminated(stopped due to ethical issues of continuing control group without treatment)
Treatment of Binge Eating in Obese Patients in Primary Care [NCT00537810]Phase 4104 participants (Actual)Interventional2007-09-30Completed
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Examine the Longer-Term Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Obese Subjects [NCT00645255]Phase 3466 participants (Actual)Interventional1998-09-30Terminated
Effects of Weight Loss in Obese Difficult-to-treat Asthmatics: a Pilot Study [NCT01047657]Phase 333 participants (Actual)Interventional2009-11-30Completed
Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care [NCT00829283]191 participants (Actual)Interventional2008-11-30Completed
"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention" [NCT01023139]100 participants (Anticipated)Interventional2009-04-30Recruiting
Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea [NCT00729963]Phase 445 participants (Actual)Interventional2004-01-31Completed
A Functional Magnetic Resonance Imaging (fMRI) Study of the Reproducibility and the Effect of Sibutramine During Fasted and Fed Conditions in Healthy Overweight and Obese Men [NCT00914212]Phase 115 participants (Actual)Interventional2009-05-31Completed
Behavioral & Pharmacologic Therapy of Adolescent Obesity [NCT00212173]120 participants InterventionalCompleted
Studying the Effects of Sibutramine on Eating Behavior [NCT01170364]Phase 414 participants (Actual)Interventional2009-02-28Terminated(stopped due to Terminated due to sibutramine being withdrawn from the market.)
Effects of Clopidogrel and Clarithromycin on the Disposition of Sibutramine and Its Active Metabolites M1 and M2 in Relation to CYP2B6*6 Polymorphism [NCT01421706]Phase 120 participants (Actual)Interventional2008-07-31Completed
Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients [NCT00941382]Phase 360 participants (Anticipated)Interventional2008-11-30Active, not recruiting
Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS: a Randomized, 24-Week Study [NCT00463112]Phase 480 participants Interventional2004-03-31Completed
A 24-Week, Blinded, Randomized, Placebo-Controlled Dose-Ranging Trial of Nasal PYY3-36 for Weight Loss in Healthy Obese Patients [NCT00537420]Phase 2551 participants (Actual)Interventional2007-10-31Completed
The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome [NCT01475019]Phase 4200 participants (Anticipated)Interventional2004-01-31Active, not recruiting
Safety and Weight Reduction of Sibutramine in the Treatment of Thai Obese and Overweight Subjects [NCT00234988]Phase 493 participants (Actual)Interventional2004-06-30Completed
A 6-Month, Randomized, Double-Blind, Placebo And Positive-Controlled Phase 2b Study To Evaluate The Effect Of Various Doses Of CP-945,598 On Weight Loss In Obese Subjects [NCT00134199]Phase 2/Phase 3282 participants (Actual)Interventional2005-03-31Completed
A Randomized, Parallel-Group, Multicenter Study to Examine the Safety, Tolerability, and Body Weight Effect of Subcutaneous Pramlintide Alone and in Combination With the Oral Antiobesity Agents Sibutramine or Phentermine in Overweight and Obese Subjects [NCT00402077]Phase 2258 participants (Actual)Interventional2006-11-30Completed
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder [NCT00402584]Phase 3304 participants (Actual)Interventional2000-08-31Completed
Pharmacogenomics of Weight Loss With Sibutramine in Obese and Overweight Patients [NCT00433641]Phase 4181 participants (Actual)Interventional2006-07-31Completed
Use of Sibutramine in Smoking Cessation [NCT00037752]436 participants (Actual)Interventional2002-09-30Completed
The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder [NCT00044187]Phase 4130 participants Interventional2001-04-30Completed
A Double-Blind, Placebo-Controlled, Comparative Study of KES524 in Patients With Obesity Disease [NCT00165685]Phase 30 participants Interventional2004-07-31Completed
A 12 Month Study to Assess Safety and Efficacy of Meridia (Sibutramine Hydrochloride Monohydrate) 10 and 15 mg in Obese Adolescents [NCT00261911]Phase 3498 participants (Actual)Interventional2000-07-31Completed
Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity [NCT00330525]Phase 272 participants (Actual)Interventional2005-01-31Completed
A Single-blind, Randomised, Placebo-controlled, Parallel Group, Incomplete Block Design, Benchmark Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects [NCT01597609]Phase 160 participants (Actual)Interventional2008-05-22Completed
An Open-label, Multicentre, Randomized Comparative Study to Evaluate the Efficacy and Safety of Using the Sibutramin-containing Drugs Reduxin® Forte and Reduxin® in Patients With Alimentary Obesity [NCT05821543]Phase 4240 participants (Actual)Interventional2020-07-03Completed
Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event [NCT00234832]Phase 310,777 participants (Actual)Interventional2003-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00115063 (6) [back to overview]Change in Duke Activity Status Index (DASI) Questionnaire Score
NCT00115063 (6) [back to overview]Change in Fasting Plasma Glucose (FPG) in Milligrams Per Deciliter (mg/dL)
NCT00115063 (6) [back to overview]Change in Weight From Baseline in Kilograms (kg)
NCT00115063 (6) [back to overview]Percent Change From Baseline Weight
NCT00115063 (6) [back to overview]Change in Blood Pressure
NCT00115063 (6) [back to overview]Percent Change in Blood Tests- Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Triglycerides and Uric Acid
NCT00234832 (7) [back to overview]Risk of Death From Any Cause (All-cause Mortality)
NCT00234832 (7) [back to overview]Risk of Experiencing a Nonfatal MI Included in the POE
NCT00234832 (7) [back to overview]Risk of Experiencing a Nonfatal Stroke Included in the POE
NCT00234832 (7) [back to overview]Risk of Experiencing a POE or a Revascularization Procedure
NCT00234832 (7) [back to overview]Risk of Experiencing a Resuscitated Cardiac Arrest Included in the POE
NCT00234832 (7) [back to overview]Risk of Experiencing Cardiovascular Death Included in the POE
NCT00234832 (7) [back to overview]Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)
NCT00537810 (2) [back to overview]BMI
NCT00537810 (2) [back to overview]Binge Eating (Remission)
NCT00829283 (2) [back to overview]BMI
NCT00829283 (2) [back to overview]Number of Subjects Who Reached Binge Eating Remission
NCT00993421 (14) [back to overview]Change From Baseline for Obesity Weight Loss Quality of Life Instrument (OWL-QoL)
NCT00993421 (14) [back to overview]Change From Baseline in Vitality Scale of Medical Outcomes Short Form - 36 (SF-36) Scale
NCT00993421 (14) [back to overview]Change in Heart Rate From Baseline to 24 Week Endpoint
NCT00993421 (14) [back to overview]Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to 24 Weeks Endpoint
NCT00993421 (14) [back to overview]Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to 24 Weeks Endpoint
NCT00993421 (14) [back to overview]Change in Total Cholesterol From Baseline to 24 Weeks Endpoint
NCT00993421 (14) [back to overview]Change in Triglycerides From Baseline to 24 Weeks Endpoint
NCT00993421 (14) [back to overview]Change in Waist Circumference From Baseline to 24 Week Endpoint
NCT00993421 (14) [back to overview]Percent Change in Body Weight From Baseline to 24 Week Endpoint
NCT00993421 (14) [back to overview]Percentage Change in Waist Circumference From Baseline to 24 Week Endpoint
NCT00993421 (14) [back to overview]Percentage of Participants Who Achieve a Minimum of 10% Weight Loss From Baseline at 24 Weeks
NCT00993421 (14) [back to overview]The Mean Change in Body Weight From Baseline to 24 Week Endpoint
NCT00993421 (14) [back to overview]Change in Blood Pressure From Baseline to 24 Week Endpoint
NCT00993421 (14) [back to overview]Change in Body Composition Using Dual Energy X-ray Absorptiometry (DXA) From Baseline to 24 Week Endpoint
NCT01170364 (1) [back to overview]24 Hour Measured Caloric Intake

Change in Duke Activity Status Index (DASI) Questionnaire Score

The DASI was used to access changes in fuctional capacity during the study. The highest score possible is 58.2 and the lowest is 0. The score for each individual question varied depending on the intensity of the activity being evaluated. The higher the score, the more physically active a person is to this set of activities of daily living questions. (NCT00115063)
Timeframe: Baseline, 2 years

Interventionunits on a scale (Mean)
Intensive Medical Intervention-2.1
Access to Weight Loss Informational Website-11.6

[back to top]

Change in Fasting Plasma Glucose (FPG) in Milligrams Per Deciliter (mg/dL)

(NCT00115063)
Timeframe: Baseline, 2 years

Interventionmg/dL (Mean)
Intensive Medical Intervention2.4
Access to Weight Loss Informational Website6.7

[back to top]

Change in Weight From Baseline in Kilograms (kg)

(NCT00115063)
Timeframe: Baseline, 2 years

Interventionkg (Mean)
Intensive Medical Intervention-12.7
Access to Weight Loss Informational Website-0.5

[back to top]

Percent Change From Baseline Weight

(NCT00115063)
Timeframe: Baseline, 2 years

InterventionPercent change (Mean)
Intensive Medical Intervention-9.7
Access to Weight Loss Informational Website-0.4

[back to top]

Change in Blood Pressure

(NCT00115063)
Timeframe: Baseline, 2 years

,
Interventionmillimeter of mercury (mm Hg) (Mean)
systolic blood pressuredystolic blood pressure
Access to Weight Loss Informational Website-8.6-3.2
Intensive Medical Intervention-14.7-4.4

[back to top]

Percent Change in Blood Tests- Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Triglycerides and Uric Acid

(NCT00115063)
Timeframe: Baseline, 2 years

,
InterventionPercent change (Mean)
LDLHDLTriglyceridesUric Acid
Access to Weight Loss Informational Website0.71.5-4.83.1
Intensive Medical Intervention1.87.9-9.2-3.0

[back to top]

Risk of Death From Any Cause (All-cause Mortality)

For each subject who died, the time to death was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

InterventionParticipants (Number)
Randomized Sibutramine418
Randomized Placebo404

[back to top]

Risk of Experiencing a Nonfatal MI Included in the POE

For each subject, the first occurrence of a nonfatal MI included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

InterventionParticipants (Number)
Randomized Sibutramine200
Randomized Placebo159

[back to top]

Risk of Experiencing a Nonfatal Stroke Included in the POE

For each subject, the time to first occurrence of a nonfatal stroke included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

InterventionParticipants (Number)
Randomized Sibutramine127
Randomized Placebo95

[back to top]

Risk of Experiencing a POE or a Revascularization Procedure

This outcome includes nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, CV death (including events such as fatal MI and fatal stroke), and any of the following revascularization procedures: percutaneous transluminal coronary angioplasty, coronary artery bypass graft, coronary artery stent placement, cardiac transplant, peripheral vascular bypass or angioplasty, and carotid endarterectomy. For each subject, the POE or revascularization status (yes/no) and time to first occurrence of an event using time-to-event analysis were evaluated. (NCT00234832)
Timeframe: From randomization up to 6 years

InterventionParticipants (Number)
Randomized Sibutramine927
Randomized Placebo856

[back to top]

Risk of Experiencing a Resuscitated Cardiac Arrest Included in the POE

For each subject, the time to first occurrence of a resuscitated cardiac arrest included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

InterventionParticipants (Number)
Randomized Sibutramine11
Randomized Placebo7

[back to top]

Risk of Experiencing Cardiovascular Death Included in the POE

For each subject, the time to cardiovascular death included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

InterventionParticipants (Number)
Randomized Sibutramine223
Randomized Placebo229

[back to top]

Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)

For each subject, POE status (with/without an event) and time to first occurrence of a POE using time-to-event analysis were evaluated. All POE confirmed by an independent adjudication committee were included in the analysis. (NCT00234832)
Timeframe: From randomization up to 6 years

,,,,,,,
InterventionParticipants (Number)
Intent-to-treat population
CV + DM Randomized to Placebo346
CV + DM Randomized to Sibutramine403
CV Only Randomized to Placebo66
CV Only Randomized to Sibutramine77
DM Only Randomized to Placebo77
DM Only Randomized to Sibutramine79
Randomized Placebo490
Randomized Sibutramine561

[back to top]

BMI

BMI (kg/m^2) was measured 4 months after treatment. (NCT00537810)
Timeframe: 4 months

InterventionBMI (kg/m^2) (Mean)
Sibutramine38.4
Placebo39.6
Placebo/CBTsh35.9
Sibutramine/CBTsh35.6

[back to top]

Binge Eating (Remission)

Remission from binge eating (zero binge episodes during previous 28 days) (NCT00537810)
Timeframe: 4 months treatment; 6 and 12 month follow up post treatment

,,,
Interventionparticipants (Number)
Remission at Post-treatmentRemission at 6 month follow upRemission at 12 month follow up
Placebo81110
Placebo/CBTsh61010
Sibutramine1055
Sibutramine/CBTsh61311

[back to top]

BMI

The body mass index is a value derived from the mass and height of an individual. The BMI is defined as the body mass divided by the square of the body height, and is universally expressed in units of kg/m^2. (NCT00829283)
Timeframe: 12 months follow-up post-treatment

Interventionkg/m^2 (Mean)
Standard Care35.9
Stepped-care37.1

[back to top]

Number of Subjects Who Reached Binge Eating Remission

Binge Remission (abstinence from binge eating) (NCT00829283)
Timeframe: 12 months follow-up

Interventionparticipants (Number)
Standard Care16
Stepped-care65

[back to top]

Change From Baseline for Obesity Weight Loss Quality of Life Instrument (OWL-QoL)

Results presented as Least Squares Mean with treatment, visit, and their interaction as fixed effects, subject as random effect, baseline body mass index used as covariate. OWL-QoL consists of 17 items on scale ranging from 0 (Not at all) to 6 (A very great deal). Before calculating scores, each item is reversed. A single quality of life score is computed by summing each item and transforming this raw score onto standardized scale of 0 (greatest impact) to 100 (lowest impact) using formula: score = [(sum of component items score (minus) lowest possible score/ possible raw score range)*100]. (NCT00993421)
Timeframe: Baseline, 24 weeks

Interventionunits on a scale (Least Squares Mean)
Placebo11.71
LY377604 (75 mg)2.67
Sibutramine (30 mg)/Metoprolol (200 mg)13.96
LY377604 (15 mg)/Sibutramine (30 mg)16.52
LY377604 (40 mg)/Sibutramine (30 mg)17.44
LY377604 (75 mg)/Sibutramine (30 mg)13.53
LY377604 (75 mg)/Sibutramine (15 mg)14.02

[back to top]

Change From Baseline in Vitality Scale of Medical Outcomes Short Form - 36 (SF-36) Scale

Vitality change from baseline is presented as Least Squares Mean (LSMean) with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline body mass index was used as covariate. SF-36 is a self-reported questionnaire that consists of 36 questions covering 8 health domains including vitality. The vitality domain results are presented. The vitality domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. (NCT00993421)
Timeframe: Baseline, 24 weeks

Interventionunits on a scale (Least Squares Mean)
Placebo10.79
LY377604 (75 mg)5.83
Sibutramine (30 mg)/Metoprolol (200 mg)16.81
LY377604 (15 mg)/Sibutramine (30 mg)10.69
LY377604 (40 mg)/Sibutramine (30 mg)7.35
LY377604 (75 mg)/Sibutramine (30 mg)10.62
LY377604 (75 mg)/Sibutramine (15 mg)13.61

[back to top]

Change in Heart Rate From Baseline to 24 Week Endpoint

Heart rate change from baseline is presented as Least Squares Mean (LSMean) with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline heart rate, age, gender were used as covariates. (NCT00993421)
Timeframe: Baseline, 24 weeks

Interventionbeats per minute (bpm) (Least Squares Mean)
Placebo-0.69
LY377604 (75 mg)-3.34
Sibutramine (30 mg)/Metoprolol (200 mg)-1.37
LY377604 (15 mg)/Sibutramine (30 mg)6.11
LY377604 (40 mg)/Sibutramine (30 mg)2.19
LY377604 (75 mg)/Sibutramine (30 mg)-2.66
LY377604 (75 mg)/Sibutramine (15 mg)-2.46

[back to top]

Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to 24 Weeks Endpoint

(NCT00993421)
Timeframe: Baseline, 24 weeks

Interventionmillimole/Liter (mmol/L) (Mean)
Placebo-0.02
LY377604 (75 mg)-0.05
Sibutramine (30 mg)/Metoprolol (200 mg)-0.03
LY377604 (15 mg)/Sibutramine (30 mg)0.01
LY377604 (40 mg)/Sibutramine (30 mg)0.06
LY377604 (75 mg)/Sibutramine (30 mg)0.01
LY377604 (75 mg)/Sibutramine (15 mg)-0.04

[back to top]

Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to 24 Weeks Endpoint

(NCT00993421)
Timeframe: Baseline, 24 weeks

Interventionmillimole/Liter (mmol/L) (Mean)
Placebo-0.07
LY377604 (75 mg)-0.03
Sibutramine (30 mg)/Metoprolol (200 mg)0.00
LY377604 (15 mg)/Sibutramine (30 mg)-0.00
LY377604 (40 mg)/Sibutramine (30 mg)-0.07
LY377604 (75 mg)/Sibutramine (30 mg)0.16
LY377604 (75 mg)/Sibutramine (15 mg)-0.16

[back to top]

Change in Total Cholesterol From Baseline to 24 Weeks Endpoint

(NCT00993421)
Timeframe: Baseline, 24 weeks

Interventionmillimole/Liter (mmol/L) (Mean)
Placebo-0.12
LY377604 (75 mg)-0.13
Sibutramine (30 mg)/Metoprolol (200 mg)-0.04
LY377604 (15 mg)/Sibutramine (30 mg)-0.01
LY377604 (40 mg)/Sibutramine (30 mg)0.00
LY377604 (75 mg)/Sibutramine (30 mg)0.17
LY377604 (75 mg)/Sibutramine (15 mg)-0.13

[back to top]

Change in Triglycerides From Baseline to 24 Weeks Endpoint

(NCT00993421)
Timeframe: Baseline, 24 weeks

Interventionmillimole/Liter (mmol/L) (Mean)
Placebo-0.06
LY377604 (75 mg)-0.11
Sibutramine (30 mg)/Metoprolol (200 mg)-0.04
LY377604 (15 mg)/Sibutramine (30 mg)0.04
LY377604 (40 mg)/Sibutramine (30 mg)0.04
LY377604 (75 mg)/Sibutramine (30 mg)0.03
LY377604 (75 mg)/Sibutramine (15 mg)0.22

[back to top]

Change in Waist Circumference From Baseline to 24 Week Endpoint

Change from baseline to endpoint is presented as LSMEAN with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline waist circumference, age, gender were used as covariates. (NCT00993421)
Timeframe: Baseline, 24 weeks

Interventioncentimeter (cm) (Least Squares Mean)
Placebo-6.58
LY377604 (75 mg)-2.51
Sibutramine (30 mg)/Metoprolol (200 mg)-8.84
LY377604 (15 mg)/Sibutramine (30 mg)-6.76
LY377604 (40 mg)/Sibutramine (30 mg)-3.57
LY377604 (75 mg)/Sibutramine (30 mg)-3.55
LY377604 (75 mg)/Sibutramine (15 mg)-8.67

[back to top]

Percent Change in Body Weight From Baseline to 24 Week Endpoint

Body weight percentage change from baseline is presented as Least Squares Mean (LSMean) with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline body weight, age, gender were used as covariates. (NCT00993421)
Timeframe: Baseline, 24 weeks

Interventionpercent change (Least Squares Mean)
Placebo-2.21
LY377604 (75 mg)0.48
Sibutramine (30 mg)/Metoprolol (200 mg)-6.12
LY377604 (15 mg)/Sibutramine (30 mg)-8.53
LY377604 (40 mg)/Sibutramine (30 mg)-6.61
LY377604 (75 mg)/Sibutramine (30 mg)-7.05
LY377604 (75 mg)/Sibutramine (15 mg)-4.71

[back to top]

Percentage Change in Waist Circumference From Baseline to 24 Week Endpoint

Percentage change from baseline to endpoint is presented as LSMEAN with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline waist circumference, age, gender were used as covariates. (NCT00993421)
Timeframe: Baseline, 24 weeks

Interventionpercent change (Least Squares Mean)
Placebo-5.86
LY377604 (75 mg)-2.22
Sibutramine (30 mg)/Metoprolol (200 mg)-7.55
LY377604 (15 mg)/Sibutramine (30 mg)-5.96
LY377604 (40 mg)/Sibutramine (30 mg)-3.02
LY377604 (75 mg)/Sibutramine (30 mg)-3.11
LY377604 (75 mg)/Sibutramine (15 mg)-7.29

[back to top]

Percentage of Participants Who Achieve a Minimum of 10% Weight Loss From Baseline at 24 Weeks

(NCT00993421)
Timeframe: 24 weeks

Interventionpercentage of participants (Number)
Placebo10.2
LY377604 (75 mg)0.0
Sibutramine (30 mg)/Metoprolol (200 mg)18.8
LY377604 (15 mg)/Sibutramine (30 mg)34.7
LY377604 (40 mg)/Sibutramine (30 mg)21.2
LY377604 (75 mg)/Sibutramine (30 mg)18.0
LY377604 (75 mg)/Sibutramine (15 mg)6.5

[back to top]

The Mean Change in Body Weight From Baseline to 24 Week Endpoint

Body weight change from baseline is presented as Least Squares Mean (LSMean) with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline body weight, age, gender were used as covariates. (NCT00993421)
Timeframe: Baseline, 24 weeks

Interventionkilograms (Least Squares Mean)
Placebo-2.37
LY377604 (75 mg)0.45
Sibutramine (30 mg)/Metoprolol (200 mg)-6.41
LY377604 (15 mg)/Sibutramine (30 mg)-8.15
LY377604 (40 mg)/Sibutramine (30 mg)-6.49
LY377604 (75 mg)/Sibutramine (30 mg)-7.06
LY377604 (75 mg)/Sibutramine (15 mg)-4.68

[back to top]

Change in Blood Pressure From Baseline to 24 Week Endpoint

Blood pressure change from baseline is presented as Least Squares Mean (LSMean) with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline blood pressure, age, gender were used as covariates. (NCT00993421)
Timeframe: Baseline, 24 weeks

,,,,,,
Interventionmm Hg (Least Squares Mean)
Systolic Blood PressureDiastolic Blood Pressure
LY377604 (15 mg)/Sibutramine (30 mg)3.252.03
LY377604 (40 mg)/Sibutramine (30 mg)-1.170.13
LY377604 (75 mg)-3.59-3.84
LY377604 (75 mg)/Sibutramine (15 mg)0.95-0.38
LY377604 (75 mg)/Sibutramine (30 mg)-0.43-2.87
Placebo-2.84-2.25
Sibutramine (30 mg)/Metoprolol (200 mg)-3.77-2.51

[back to top]

Change in Body Composition Using Dual Energy X-ray Absorptiometry (DXA) From Baseline to 24 Week Endpoint

Change in body composition (lean body mass and fat mass) was assessed using dual energy x-ray absorptiometry (DXA) and is presented as LSMEAN values with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline body composition, age, gender were used as covariates. (NCT00993421)
Timeframe: Baseline, 24 weeks

,,,,,,
Interventionkilograms (kg) (Least Squares Mean)
Fat MassLean Mass
LY377604 (15 mg)/Sibutramine (30 mg)-6.13-1.85
LY377604 (40 mg)/Sibutramine (30 mg)-4.80-0.71
LY377604 (75 mg)0.540.15
LY377604 (75 mg)/Sibutramine (15 mg)-2.55-1.48
LY377604 (75 mg)/Sibutramine (30 mg)-4.29-1.08
Placebo-2.40-0.55
Sibutramine (30 mg)/Metoprolol (200 mg)-3.00-1.92

[back to top]

24 Hour Measured Caloric Intake

The primary outcome measure is 24-hour food intake assessed by 24 hour weighed intake after one week of sibutramine administration compared to one week of placebo administration. (NCT01170364)
Timeframe: 1 week

Interventionkcal (Mean)
Sibutramine1923
Placebo2373

[back to top]